(Telestock) – FSIa leading Italian institutional investor, has announced theMicol Fornaroli and Bastiano Sanna join their Life Science Team. The arrival of the two professionals strengthens FSI’s skills in the Life Sciences which, together with Technology, constitute FSI’s areas of focus.
To date, the FSI Team has invested approximately 1.5 billion euros in Life Sciences and Technology80% of the capital of the FSI I fund and all the capital called up to date of the newly established FSI II fund. By applying an investment formula based on partnership, low or no financial leverage and company growth, FSI acts as an “engine” for the development of these two strategic sectors for Italy and at the heart of the National Recovery and Resilience Plan (PNRR).
“Two professionals with experience and international fame are joining our team – declares Maurizio Tamagnini, Chief Executive Officer by FSI – The sector in which Micol and Bastiano are experts is particularly close to my heart. It is dedicated to advancing the quality of human life by solving its fundamental problems. It invests heavily in research and development, employs young graduates in particular, shows greater gender inclusiveness (women are the majority among managers and executives under 35) and attention to sustainability. Italy is a leader in Europe in pharmaceutical production, but companies are fragmented and still have a low level of openness of capital to third parties. We believe there is a great investment opportunity that a team with strong technical and scientific skills can seize”.
With more than twenty years of career in the pharmaceutical, diagnostic, med-tech and healthcare sectors, Micol Fornaroli has held various executive roles working in multinational groups, family businesses and funds. She is currently a Senior Advisor of the Global Lifescience Practice of McKinsey and a Board Member of Alliance Medical Group. She recently gained experience as an Industrial Advisor at Schulke&Mayr and managed as Chief Executive Officer the Medical Technology and Devices Group, a global leader in medical sharps. Previously, she worked at the Bracco Group, where she held the position of Chief Strategy Officer leading the activities in China, Japan, South Korea and LATAM and serving on the Board of Centro Diagnostico Italiano. Until 2012, she was Vice President Organization and Management for Global R&D at Sanofi. Previously, she was a Partner at McKinsey & Company, where she led the Pharma and Medical Products Practice for MedComplex until 2010.
Bastian Sanna Ph.D. has a solid experience in the Pharmaceuticals sector at an international level, particularly in the United States where he developed his entire career, from 2003 until his return to Italy last May. From 2020 to May 2024 he worked in Vertexa global leader in the discovery, development and commercialization of small molecule drugs primarily for the treatment of cancer, viral, inflammatory and autoimmune diseases. At Vertex, he served as Executive Vice President and Head of Cell Therapies and Gene Therapies and coordinated the Jeffrey Leiden Center for Cell and Genetic Therapies in Boston. From 2018 to 2020, he was CEO of Semma Therapeutics, a company dedicated to the development of cell therapies for people with diabetes. From 2016 to 2018, he served as Chief Operating Officer of Magenta Therapeutics, where he was responsible for operations, finance, clinical development and program management. From 2010 to 2016, he was part of the leadership team of Novartis’ Cell and Gene Therapy business, as Global Head of Stem Cell Transplant and Early Stage Programs, and was Global Head of Strategic Planning and Portfolio Management at Novartis Institutes for BioMedical Research.